The launch of a 750mcg PTH injection in Australia has been cautiously managed, with availability primarily to specialist physicians and designated treatment centers. Preliminary sales figures for this increased strength remain unavailable from the company, although industry sources suggest moderate adoption rates . Availability to patients is manag